ArticlePloS one2024

Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.

Thomas Seufferlein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.